AIDS-related Kaposi sarcoma

Kaposi Sarcoma that is caused by HUMAN HERPESVIRUS 8 infections in persons infected with HIV.

Networked: 40 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Disease Context: Research Results

Infections: 526564
Neoplasms: 1324753
- Neoplasms by Histologic Type: 2
  - Vascular Tissue Neoplasms: 141
    - Kaposi Sarcoma: 4000
      - AIDS-related Kaposi sarcoma: 40
  - Connective and Soft Tissue Neoplasms: 1
    - Sarcoma: 23140
      - Kaposi Sarcoma: 4000
        AIDS-related Kaposi sarcoma: 40
Immune System Diseases: 4321
- Immunologic Deficiency Syndromes: 91
  - HIV Infections: 25254
    - AIDS-Related Opportunistic Infections: 74
      - AIDS-related Kaposi sarcoma: 40

Related Diseases

1.	Neoplasms (Cancer)
2.	Multiple Myeloma
3.	Acquired Immunodeficiency Syndrome (AIDS)
4.	Ovarian Neoplasms (Ovarian Cancer)
5.	Breast Neoplasms (Breast Cancer)

Experts

1.	Aboulafia, David: 2 articles (01/2020 - 01/2011)
2.	Ambinder, Richard F: 2 articles (01/2020 - 04/2012)
3.	Koon, Henry B: 2 articles (04/2012 - 01/2011)
4.	Krown, Susan E: 2 articles (04/2012 - 01/2011)
5.	Dezube, Bruce J: 2 articles (01/2011 - 09/2004)
6.	Catanzaro, Andrew T: 2 articles (12/2007 - 06/2006)
7.	Little, Richard F: 2 articles (12/2007 - 06/2006)
8.	Pluda, James M: 2 articles (12/2007 - 06/2006)
9.	Steinberg, Seth M: 2 articles (12/2007 - 06/2006)
10.	Wyvill, Kathleen M: 2 articles (12/2007 - 06/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to AIDS-related Kaposi sarcoma:

1.	Paclitaxel (Taxol)FDA LinkGeneric 06/01/2008 - "Paclitaxel has proved to be highly effective in the treatment of severe AIDS-related Kaposi sarcoma (KS), for which it is now considered as a second-line monotherapy. " 11/01/2016 - "Although much research has been published on ways to overcome the low oral bioavailability of paclitaxel, exploration of novel drug delivery systems that can target paclitaxel deep in to the dermal areas in AIDS-related Kaposi sarcoma (KS) have not yet been reported. " 07/01/2002 - "Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma." 01/15/2005 - "Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). " 11/01/2003 - "It is currently approved in the United States and Europe for AIDS-related Kaposi sarcoma and platinum/paclitaxel-refractory ovarian carcinoma; in Europe and Canada, it is also approved as monotherapy for MBC. "
2.	liposomal doxorubicin (Doxil)FDA Link 05/01/1994 - "Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma." 10/01/2013 - "As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. " 12/15/2007 - "Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma." 07/17/2022 - "Nanomedicines have revolutionized the treatment of certain types of cancer, as is the case of doxil, liposomal formulation with doxorubicin encapsulated, in the treatment of certain types of ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. "
3.	Daunorubicin (Cerubidine)FDA LinkGeneric 11/01/2003 - "Liposomal daunorubicin, currently approved in the United States for the treatment of AIDS-related Kaposi sarcoma, has shown preliminary activity in MBC in a phase I trial; further investigation is ongoing. " 02/01/2002 - "Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma."
4.	Interleukin-12 (IL 12)IBA 06/15/2006 - "Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma." 06/15/2006 - "We initiated a phase 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) whose KS was progressing while on antiretroviral therapy. " 12/15/2007 - "Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma."
5.	Etoposide (VP 16)FDA LinkGeneric 04/01/2001 - "The purpose of this study was to examine the antitumor activity, toxic effects, and plasma pharmacokinetics of fractionated doses of oral etoposide aiming at the achievement of prolonged safe and active plasma drug levels in patients with AIDS-related Kaposi sarcoma (KS). " 04/01/2001 - "Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index." 01/01/1996 - "Nine patients with biopsy proven and measurable disease AIDS-related Kaposi sarcoma were treated with a continuous infusion of etoposide at a dose of 100 mg/m2 per day for 3 days every 3 weeks. " 01/01/1996 - "We conducted a preliminary phase II clinical trial to determine the toxicity, response, and survival rate of 72-hour continuous infusion etoposide administered to patients with AIDS-related Kaposi sarcoma. " 01/01/1996 - "Continuous infusion etoposide in advanced AIDS-related kaposi sarcoma."
6.	Collagen Type I (Type I Collagen)IBA 01/01/2011 - "Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. "
7.	Matrix Metalloproteinases (MMPs)IBA 01/01/2011 - "Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. "
8.	Angiogenesis InhibitorsIBA 01/01/2011 - "Using a novel blinded intrapatient vehicle control design, we conducted a phase II study of topically administered halofuginone, an angiogenesis inhibitor that inhibits collagen type-I and matrix metalloproteinases (MMPs), in patients with AIDS-related Kaposi sarcoma. "
9.	Thalidomide (Thalomid)FDA Link 01/01/2000 - "Thalidomide has shown clinical antitumor activity in single-agent, phase II clinical trials in AIDS-related Kaposi sarcoma, glioma, multiple myeloma refractory to chemotherapy, and hormone-refractory prostate cancer. "
10.	Hormones (Hormone)IBA 01/01/2000 - "Thalidomide has shown clinical antitumor activity in single-agent, phase II clinical trials in AIDS-related Kaposi sarcoma, glioma, multiple myeloma refractory to chemotherapy, and hormone-refractory prostate cancer. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 01/01/2019 - "Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya." 05/11/2008 - "To evaluate the role of highly active antiretroviral therapy and chemotherapy on tumor response among persons with AIDS-related Kaposi sarcoma and identify factors associated with response in a clinic setting. " 03/07/2023 - "AIDS-Related Kaposi Sarcoma Associated with Steroid-Unresponsive Periorbital Lymphedema that Responded to Chemotherapy." 03/07/2023 - "This report presents 2 cases of AIDS-related Kaposi sarcoma (AIDS-KS) associated with severe steroid-unresponsive periorbital lymphedema that responded to chemotherapy. " 01/01/2000 - "Thalidomide has shown clinical antitumor activity in single-agent, phase II clinical trials in AIDS-related Kaposi sarcoma, glioma, multiple myeloma refractory to chemotherapy, and hormone-refractory prostate cancer. "
2.	Therapeutics 01/01/2020 - "AIDS-related Kaposi sarcoma is often incompletely controlled, requiring serial therapies. " 12/01/2000 - "AIDS-related Kaposi sarcoma: the role of local therapy for a systemic disease." 09/01/2000 - "New therapies for the treatment of AIDS-related Kaposi sarcoma." 08/01/2010 - "Evaluation of plasma human herpesvirus 8 DNA as a marker of clinical outcomes during antiretroviral therapy for AIDS-related Kaposi sarcoma in Zimbabwe." 06/15/2006 - "We initiated a phase 1 pilot study of IL-12 in 32 patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS) whose KS was progressing while on antiretroviral therapy. "
3.	Highly Active Antiretroviral Therapy (HAART) 09/01/2004 - "In the HAART era, because CD4 cell count was shown no longer to provide prognostic information about AIDS-related Kaposi sarcoma, the traditional classification system for staging AIDS-related Kaposi sarcoma has been refined. " 01/01/2019 - "Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya." 05/11/2008 - "To evaluate the role of highly active antiretroviral therapy and chemotherapy on tumor response among persons with AIDS-related Kaposi sarcoma and identify factors associated with response in a clinic setting. " 09/01/2021 - "Despite the introduction of effective combination antiretroviral therapy (cART) AIDS-related Kaposi Sarcoma (AIDS-KS) remains the most common malignancy in HIV positive patients. " 05/01/2012 - "The prevalence of AIDS-related Kaposi sarcoma (KS) has markedly declined in the era of highly active antiretroviral therapy (HAART) although it remains one of the most common AIDS-defining malignancies. "
4.	Combination Drug Therapy (Combination Chemotherapy) 07/01/2002 - "Treatment options are limited for patients with advanced acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (AIDS-KS) whose disease has progressed after receiving therapy with liposomal anthracyclines or combination chemotherapy with doxorubicin (Adriamycin), bleomycin, and vincristine (ABV). "